← ANALYST RATINGS · TIPRANKS
Nautilus Biotechnolgy (NAUT): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $3.83, the highest $4.00, the lowest $3.50. The average is +86.1% from the last price of $2.06.
Analyst ratings 4
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 → $2.00+33.3% | Hold | −2.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 → $2.00+33.3% | Hold | −2.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 → $2.00+33.3% | Hold | −2.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 → $2.00+33.3% | Hold | −2.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 → $2.00+33.3% | Hold | −2.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 → $2.00+33.3% | Hold | −2.9% | Reiterated | 03.10.26on TipRanks 06:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.00 → $1.50+50.0% | Hold | −27.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.00 → $1.50+50.0% | Hold | −27.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.00 → $1.50+50.0% | Hold | −27.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.00 → $1.50+50.0% | Hold | −27.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.00 → $1.50+50.0% | Hold | −27.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.00 → $1.50+50.0% | Hold | −27.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| Max Masucci★★★★★★★★★★#2606 · hits 42% · avg +8.5% | Roth MKM | $3.50 | Buy | +69.9% | Initiated | 29.09.26on TipRanks 05:05 | +23.2%next day +4.2% · 5 days +27.7% | ↗ |
| Unknown Analyst | Leerink Partners | $4.00 | Buy | +94.2% | Initiated | 09.09.26on TipRanks Sep 10 09:05 | +21.3%next day −11.1% · 5 days −12.1% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $4.00 | Buy | +94.2% | Reiterated | 28.07.26on TipRanks Jul 29 07:41 | −27.9%next day −11.8% · 5 days −22.0% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | — | Buy | — | Reiterated | 28.04.26on TipRanks 15:45 | +1.3%next day −3.5% · 5 days +8.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Nautilus Biotechnolgy
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.83 at a price of $1.42 (+170.0%); now: $3.83 at $2.06 (+86.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 3 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 27.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.14 (from $-0.15 to $-0.13). Last quarter: $-0.11.
Best top-analyst consensus in the sector · Healthcare
About Nautilus Biotechnolgy
- CEO: Sujal Patel
- Employees: 127
- 2701 Eastlake Avenue East, Seattle, WA, 98102, US
- www.nautilus.bio
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Data from the stock’s TipRanks forecast page, read 141 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗